Healthcare Services M&A Multiples Report 2026: Valuation Benchmarks by Size and Segment

Last updated: July 1, 2026. Report vintage: covers deal activity closed 2021 through Q2 2026. Rate context: US 10-year Treasury 4.10 to 4.55 percent range across H1 2026; Fed Funds target 3.75 to 4.00 percent following the March 2026 cut. Author: CT Acquisitions research desk.

This report is for general informational purposes. It is not a valuation opinion, appraisal, guarantee, or prediction. It is not investment, legal, tax, or financial advice. Specific outcomes depend on a full analysis of the individual business.

Executive Summary

Key Findings

The following fifteen statements are the most quotable, defensible findings in this report. Each carries earnings basis, size band, vintage, and named source.

1. In 2025, US private-company healthcare services businesses at the $10M to $25M enterprise value tier have tended to trade in the range of 7.4x to 9.1x adjusted EBITDA, according to GF Data Resources “Valuation Metrics” annual review for FY2025 (published March 2026).
2. In Q1 2026, small-business healthcare services listings sold on brokered marketplaces (median asking price $520,000) have tended to trade at a median of 2.5x SDE, according to BizBuySell Insight Report Q1 2026.
3. In FY2024 and FY2025, disclosed dental support organization (DSO) platform transactions ($20M+ adjusted EBITDA) have been reported in the range of 12.0x to 18.0x adjusted EBITDA, according to Provident Healthcare Partners “Dental Services M&A Update” Q4 2024 and cross-referenced against Group Dentistry Now sponsor recap Q1 2026.
4. In 2024 to 2025, veterinary hospital platform acquisitions ($10M+ adjusted EBITDA) have been reported trading in the range of 13.0x to 17.0x adjusted EBITDA, per Capstone Partners “Veterinary Services M&A” Q2 2025.
5. In 2024 to Q1 2026, hospice platform-tier transactions ($15M+ adjusted EBITDA, Medicare-certified) have been reported at 11.0x to 14.5x adjusted EBITDA, according to Stoneridge Partners “Home Care and Hospice Report” 2025 and Chemed Corp 10-K FY2024 (VITAS reporting segment operating margin approximately 19.4 percent).
6. In FY2025, US Physical Therapy Inc (NYSE: USPH) 10-K FY2025 reported acquiring 26 outpatient physical therapy clinic acquisitions at a blended purchase price implying a weighted average multiple of approximately 7.2x acquired-clinic contribution margin (labeled by USPH as “adjusted EBITDA equivalent”), filed March 2026.
7. In 2024 to Q1 2026, behavioral health services (outpatient substance use disorder + autism / ABA + mental health) platform transactions have been reported in the range of 9.0x to 14.0x adjusted EBITDA at the $10M+ adjusted EBITDA tier, per Capstone Partners “Behavioral Health M&A” year-end 2024 and Provident Healthcare Partners Q3 2025 update.
8. In 2024, disclosed dermatology consolidator platform transactions ($15M+ adjusted EBITDA) have been reported at 9.0x to 13.0x adjusted EBITDA, softer than the 11.0x to 15.0x range widely reported in 2021, per Provident Healthcare Partners “Dermatology M&A Update” Q4 2024 and Modern Healthcare year-end 2024 sector recap.
9. In 2024 to 2025, optometry consolidator platform activity ($10M+ adjusted EBITDA) has been reported at 8.5x to 12.5x adjusted EBITDA, per Provident Healthcare Partners Q4 2024 outlook and cross-referenced Vision Monday sponsor recap 2025.
10. In 2024 to 2025, medical spa platforms ($5M+ adjusted EBITDA, injectables-led) have been reported trading at 9.0x to 12.0x adjusted EBITDA, according to Skytale Group “Medical Spa State of the Industry Report” 2025.
11. Across the sub-$1M SDE tier in the cluster, single-office healthcare service businesses (dental, optometry, vet, PT, single-room med spa) have tended to trade at 1.9x to 3.6x SDE during 2024 to Q1 2026, per BizBuySell Insight Report Q1 2026 and IBBA Market Pulse Q4 2025.
12. The observed platform-to-add-on arbitrage spread across the healthcare services cluster has been roughly 4.0 to 8.0 turns of adjusted EBITDA in 2024 to Q1 2026, per GF Data healthcare-segment breakout FY2025 and Provident Healthcare Partners “Rollup Economics Update” Q3 2024.
13. In IBBA Market Pulse Q4 2025, the average cash at close on LMM healthcare deals ($2M to $50M enterprise value) was reported at 77.3 percent of total consideration, versus 83.9 percent in Q4 2021.
14. In 2024 to 2025, disclosed R&W insurance-backed transactions in healthcare services with enterprise value $30M+ have carried R&W premium rates of approximately 2.5 to 4.0 percent of the R&W limit purchased, per Marsh “Transactional Risk 2024 Insurance Market Update” and Aon “M&A and Transaction Solutions Year in Review 2024”.
15. In FY2024, Chemed Corp reported VITAS Healthcare (hospice segment) net service revenue of $1.475 billion with segment operating income of approximately $285.9 million (implied 19.4 percent operating margin), a public-market reference commonly cited as the ceiling proxy for private hospice adjusted EBITDA margins, per Chemed Corp 10-K FY2024 filed Feb 2025.

Multiples by Size Band (The Spine)

The following table is the extractable core of this report. Never blend SDE and adjusted EBITDA in a single row. Read the “Earnings basis” column carefully. Sub-$1M businesses in the LMM are typically transacted on an SDE basis (owner-benefit inclusive of a working owner’s compensation). Businesses at $1M+ adjusted EBITDA are typically transacted on an adjusted EBITDA basis (owner-compensation normalized to fair-market replacement).

Size band	Earnings basis	Low observed	Typical (median band)	High observed	Vintage	Primary source
Under $1M SDE (small business, single-location)	SDE	1.9x	2.4x to 2.9x	3.6x	2024 to Q1 2026	BizBuySell Insight Report Q1 2026; IBBA Market Pulse Q4 2025
$1M to $3M adjusted EBITDA (LMM add-on, single or dual location)	Adjusted EBITDA	5.0x	6.0x to 7.5x	8.5x	2024 to Q1 2026	GF Data $10-25M EV cut FY2025; Provident Healthcare Partners Q4 2024
$3M to $10M adjusted EBITDA (mid-LMM, multi-location)	Adjusted EBITDA	6.5x	7.5x to 9.5x	11.0x	2024 to Q1 2026	GF Data $25-50M EV cut FY2025; Capstone Partners healthcare M&A Q4 2025
$10M+ adjusted EBITDA (platform / consolidator)	Adjusted EBITDA	8.5x	10.0x to 13.5x	15.5x+	2024 to Q1 2026	Provident Healthcare Partners sector reports 2024-2025; Baird Global Healthcare year-end 2024; sub-segment adjustments below
Revenue-basis (loss-making platform, growth-stage tele-health / outpatient care)	Revenue	0.7x	1.2x to 2.5x	4.0x+	2024 to Q1 2026	PitchBook Q4 2025 healthcare venture and growth summary (used only when EBITDA is not the operative multiple)

Reading the spine

The typical (median) band column reflects the interquartile range where the bulk of observed transactions have clustered. Businesses at the low end tend to carry one or more of: heavy owner dependency, thin recurring revenue, concentrated payer or referral relationships, or non-core geographies. Businesses at the high end tend to combine multi-location scale, embedded management, strong recurring or repeat-visit revenue, favorable payer mix, and defensible geographic density that supports add-on activity.

Do not read this table as an appraisal. It is a compilation of observed ranges. The same $2M-adjusted-EBITDA business could reasonably clear at 5.5x or at 8.0x depending on payer mix, referral source concentration, provider retention, and the specific sub-segment (see the sub-segment section below). For owner-dependency effects specifically, see the internal reference at how owner dependency affects valuation.

Vintage caveat

The 2024 to Q1 2026 vintage sits in a rate environment (US 10-year Treasury 4.10 to 4.55 percent through H1 2026, Fed Funds 3.75 to 4.00 percent post March 2026 cut) that is materially different from the 2020 to Q1 2022 vintage most legacy multiples reports were built on (10-year Treasury 0.6 to 2.0 percent, Fed Funds 0.00 to 0.25 percent). Multiples in the current vintage sit 1.5 to 3.0 turns below the 2020-2021 peak in most cluster sub-segments, per GF Data year-over-year comparisons FY2021 versus FY2025 and Capstone Partners “Healthcare M&A Retrospective” Q4 2024. Any user pulling numbers from a pre-2023 valuation reference should apply that adjustment before quoting.

Multiples by Sub-Segment

Each sub-segment is treated at comparative depth. Deeper per-vertical treatments are pending as spoke pages (flagged in the Build Notes appendix).

Dental and DSOs

Independent single-office dental practices sit at the smallest end. In 2024 to Q1 2026, single-office general dentistry practices with under $1M SDE have tended to trade at 1.7x to 2.9x SDE, per ADA Health Policy Institute practice transitions summary Feb 2026 and BizBuySell dental cut Q1 2026. Specialty single-office practices (orthodontics, endodontics, oral surgery, pediatric dentistry) have carried a modest premium of roughly 0.3 to 0.7 turns SDE above general dentistry at the same size tier, per ADA Health Policy Institute Feb 2026.

At the multi-office scaling tier, dental groups with $1M to $3M adjusted EBITDA have been reported trading at 5.5x to 8.5x adjusted EBITDA in 2024 to Q1 2026, per Provident Healthcare Partners “Dental Services M&A Update” Q4 2024. At the $3M to $10M adjusted EBITDA tier, ranges have widened to 7.5x to 12.0x adjusted EBITDA, per the same source.

DSO platform transactions ($15M+ adjusted EBITDA) have been reported in the range of 12.0x to 18.0x adjusted EBITDA during FY2024 to Q1 2026, per Provident Healthcare Partners Q4 2024 and Group Dentistry Now sponsor recap Q1 2026. That range has softened from the roughly 13.0x to 20.0x widely reported for platform DSO transactions at the 2021 peak, per Group Dentistry Now year-in-review 2021. Top-of-range platforms in 2024 to 2025 have tended to combine 40+ locations, sub-15 percent revenue from Medicaid, embedded regional-manager layer, physician-owner retention agreements of at least three years, and specialty mix (implants, orthodontics, sedation) accretive to per-visit revenue. Bottom-of-range platforms have tended to carry regionally concentrated footprints, higher Medicaid exposure, or unresolved dentist-recruitment issues.

A dedicated DSO deep-dive is pending internal link at /guides/dental-dso-ma-multiples-2026/ (parallel build, wire at end of Batch 1).

Veterinary

The veterinary sub-segment saw the sharpest multiple compression in the cluster from the 2020-2021 peak. Single-location practices with under $1M SDE have tended to trade at 2.0x to 3.4x SDE during 2024 to Q1 2026, per AVMA-cited AAHA practice management data 2025 and BizBuySell veterinary cut Q1 2026.

Multi-hospital groups at $1M to $3M adjusted EBITDA have been reported at 6.0x to 9.0x adjusted EBITDA in 2024 to 2025, per Capstone Partners “Veterinary Services M&A” Q2 2025. At the $3M to $10M adjusted EBITDA tier, ranges have been reported at 8.5x to 13.0x adjusted EBITDA, per the same source.

Platform-tier veterinary hospital groups ($10M+ adjusted EBITDA) have been reported trading at 13.0x to 17.0x adjusted EBITDA in 2024 to 2025, per Capstone Partners Q2 2025. That range compares against widely reported 2021-peak ranges of roughly 15.0x to 20.0x for platform vet transactions, per Baird Global Healthcare year-end 2021 recap. Consolidator activity from Mars Petcare (Banfield, VCA, BluePearl), National Veterinary Associates (JAB Holding Company), Southern Veterinary Partners (Shore Capital + Silversmith), and Ethos Veterinary Health (Nestle Purina PetCare) has been widely reported in trade press, though specific transaction multiples on individual practice acquisitions are almost never publicly disclosed. Treat any single-deal multiple in this segment with skepticism unless it is disclosed by a public-company acquirer.

A dedicated veterinary deep-dive is pending internal link at /guides/veterinary-practice-ma-multiples-2026/ (parallel build, wire at end of Batch 1).

Dermatology

Dermatology M&A activity peaked in 2020-2021 and has softened. In 2024 to Q1 2026, independent single-office dermatology practices with under $1M SDE have tended to trade at 2.3x to 3.6x SDE, per Modern Healthcare year-end 2024 sub-sector recap and IBBA Market Pulse Q4 2025 healthcare cut.

Multi-location dermatology groups at $1M to $3M adjusted EBITDA have been reported at 6.0x to 9.0x adjusted EBITDA in 2024 to Q1 2026, per Provident Healthcare Partners “Dermatology M&A Update” Q4 2024. At the $3M to $10M adjusted EBITDA tier, ranges have been reported at 7.5x to 11.5x adjusted EBITDA, per the same source.

Platform-tier dermatology consolidator transactions ($15M+ adjusted EBITDA) have been reported at 9.0x to 13.0x adjusted EBITDA in 2024, per Provident Healthcare Partners Q4 2024. Modern Healthcare year-end 2024 flagged the sector as having repriced roughly 2.0 to 3.5 turns off the 2021 peak. Top-of-range platforms have tended to carry a favorable specialty mix (Mohs surgery + cosmetic + pathology), meaningful ownership of on-site pathology or Mohs lab (which drives ancillary revenue capture), and physician-owner retention of at least five years. Bottom-of-range platforms have tended to carry concentrated cosmetic revenue (more discretionary and rate-sensitive) or unresolved corporate practice of medicine (CPOM) structure questions in states like California, New York, and Texas.

Medical Spa (Aesthetics)

Medical spas are a hybrid of healthcare services and consumer discretionary. In 2024 to Q1 2026, single-location med spas with under $1M SDE have tended to trade at 1.8x to 3.2x SDE, per BizBuySell “Beauty and Personal Care” and “Medical Practice” combined cut Q1 2026 and Skytale Group 2025 report.

Multi-location injectables-led med spa groups at $1M to $3M adjusted EBITDA have been reported at 5.5x to 8.5x adjusted EBITDA in 2024 to Q1 2026, per Skytale Group 2025. At the $3M to $10M adjusted EBITDA tier, ranges have been reported at 7.5x to 11.0x adjusted EBITDA, per the same source.

Platform-tier med spa consolidator transactions ($5M+ adjusted EBITDA) have been reported at 9.0x to 12.0x adjusted EBITDA in 2024 to 2025, per Skytale Group 2025. Top-of-range platforms have combined 15+ locations, injectables share of at least 60 percent of revenue (higher gross margin and repeat cadence than laser or aesthetic devices), NP/PA-driven staffing model (as opposed to MD-dependent), and membership program penetration of at least 25 percent of active patients. Bottom-of-range platforms have carried heavy laser and body-contouring capital exposure (equipment financing overhang), thin membership share, or regulatory questions on medical director oversight structure.

Optometry

Optometry M&A has been quieter than dental and vet but has followed a similar arc. In 2024 to Q1 2026, independent single-office optometry practices with under $1M SDE have tended to trade at 1.9x to 3.2x SDE, per Vision Monday sponsor recap 2025 and BizBuySell optometry cut Q1 2026.

Multi-location optometry groups at $1M to $3M adjusted EBITDA have been reported at 5.5x to 8.0x adjusted EBITDA in 2024 to Q1 2026, per Provident Healthcare Partners “Optometry M&A” Q4 2024 outlook. At the $3M to $10M adjusted EBITDA tier, ranges have been reported at 7.0x to 10.5x adjusted EBITDA, per the same source.

Platform-tier optometry consolidator transactions ($10M+ adjusted EBITDA) have been reported at 8.5x to 12.5x adjusted EBITDA in 2024 to 2025, per Provident Healthcare Partners Q4 2024 outlook and Vision Monday sponsor activity summary 2025. Consolidator activity has been reported involving MyEyeDr (Goldman Sachs Asset Management), EyeCare Partners (Partners Group), and Vision Innovation Partners (Centre Partners). Specific per-deal multiples in this segment are almost never publicly disclosed; treat single-deal figures skeptically unless disclosed via a public-company filing.

Physical Therapy (Outpatient Rehab)

Physical therapy has the cleanest public-market anchor in the cluster because of US Physical Therapy Inc (NYSE: USPH). In FY2025, USPH reported 26 clinic acquisitions at a blended purchase price implying approximately 7.2x acquired-clinic contribution margin (labeled as “adjusted EBITDA equivalent”), per USPH 10-K FY2025 filed March 2026. That figure is a useful public-market anchor for the multi-location add-on tier and should not be read as a platform multiple.

Single-location outpatient PT practices with under $1M SDE have tended to trade at 1.9x to 3.1x SDE in 2024 to Q1 2026, per APTA-referenced practice management data 2025 and BizBuySell PT cut Q1 2026. Multi-location PT groups at $1M to $3M adjusted EBITDA have been reported at 5.5x to 8.0x adjusted EBITDA in 2024 to Q1 2026, per Provident Healthcare Partners “Rehab Services M&A” Q4 2024. At the $3M to $10M adjusted EBITDA tier, ranges have been reported at 7.0x to 10.5x adjusted EBITDA.

Platform-tier PT consolidator transactions ($10M+ adjusted EBITDA) have been reported at 9.0x to 13.0x adjusted EBITDA in 2024 to 2025, per Provident Healthcare Partners Q4 2024. Top-of-range platforms have tended to carry payer diversification (no single payer above 25 percent of revenue), embedded referral-source relationships with orthopedic surgery groups, and PT-per-clinic staffing productivity of at least 3.5 FTEs per site. Bottom-of-range platforms have carried single-payer concentration (particularly workers-comp-heavy in certain states), heavy state Medicaid exposure, or unresolved reimbursement risk from the ongoing CMS multi-year outpatient therapy fee schedule changes.

Behavioral Health (Outpatient SUD, Autism/ABA, Mental Health)

Behavioral health is not one sub-segment but three distinct sub-markets with meaningfully different multiple bands. Aggregating them into a single range is misleading, but the report has to give a workable spread.

Outpatient substance use disorder (SUD) treatment groups at $10M+ adjusted EBITDA have been reported at 9.0x to 13.5x adjusted EBITDA in 2024 to 2025, per Capstone Partners “Behavioral Health M&A” year-end 2024 and Provident Healthcare Partners Q3 2025 update. Autism / applied behavior analysis (ABA) platforms at $10M+ adjusted EBITDA have been reported at 10.0x to 14.0x adjusted EBITDA during the same window. Outpatient mental health group platforms at $10M+ adjusted EBITDA have been reported at 8.5x to 12.5x adjusted EBITDA.

At the sub-$3M adjusted EBITDA tier, behavioral health group practices (any of the three sub-markets) have been reported at 5.5x to 9.0x adjusted EBITDA in 2024 to Q1 2026, per Provident Healthcare Partners Q3 2025 update. Single-location practices at the SDE tier are unusual in behavioral health M&A because scale is a critical driver of network-contract economics; observed SDE multiples for the rare sub-$1M transactions have tended to sit at 1.9x to 3.0x SDE, per BizBuySell “Medical Practices” cut Q1 2026.

Top-of-range behavioral health platforms have combined payer diversification, meaningful commercial insurance revenue share (above 50 percent), strong clinician retention (voluntary turnover under 20 percent annualized), and defensible clinical outcomes measurement infrastructure. Bottom-of-range platforms have carried Medicaid-only revenue, high clinician turnover, or unresolved audit-recovery risk (particularly in SUD).

Home Health and Hospice

Home health and hospice are two distinct businesses that trade differently. Aggregating them once again requires care.

Medicare-certified home health (skilled home nursing) group platforms at $10M+ adjusted EBITDA have been reported at 9.5x to 13.5x adjusted EBITDA in 2024 to Q1 2026, per Stoneridge Partners “Home Care and Hospice Report” 2025 and cross-referenced Provident Healthcare Partners Q3 2024 home health update.

Hospice platforms ($15M+ adjusted EBITDA, Medicare-certified) have been reported at 11.0x to 14.5x adjusted EBITDA in 2024 to Q1 2026, per Stoneridge Partners 2025 and Chemed Corp 10-K FY2024 (VITAS reporting segment: net service revenue $1.475 billion, segment operating income approximately $285.9 million, 19.4 percent operating margin) as a public-market ceiling proxy.

Non-medical home care (personal care attendants, private-pay senior services) sits at meaningfully lower multiples because of workforce economics and thinner margins. In 2024 to Q1 2026, non-medical home care groups at $1M to $3M adjusted EBITDA have been reported at 4.0x to 6.5x adjusted EBITDA, per Home Care Pulse and NAHC industry sources 2025. At the $3M to $10M adjusted EBITDA tier, ranges have been reported at 5.5x to 8.5x adjusted EBITDA.

The Amedisys and UnitedHealth Group proposed transaction, announced June 2023 at $101 per share (approximately $3.3 billion enterprise value), remained under Department of Justice antitrust review through late 2024 and cleared with divestitures in early 2025. That transaction is a widely cited public-market data point, though the implied approximately 19x FY2022 adjusted EBITDA multiple should be read as a public-market strategic-buyer premium rather than a private-market benchmark. See Amedisys Inc DEFM14A (filed August 2023) for the disclosed transaction economics.

What Moves the Multiple (Drivers)

The single most-asked question in healthcare services M&A is why one business at a given size clears at the top of its range while a similarly sized business clears at the bottom. The following drivers explain most of the variance observed.

1. Payer mix (unique to healthcare)

Payer mix is the single largest range-mover in the healthcare cluster, and it has no direct analog in the home-services cluster (see the sister report at home services M&A multiples report 2026 for comparison).

Businesses with a commercial insurance revenue share above 60 percent (and Medicaid share below 15 percent) have tended to trade at the upper half of their size-band range. Businesses with Medicaid revenue share above 30 percent have tended to trade at the lower half of their range, and businesses with single-payer concentration above 40 percent (particularly workers-comp or single-state Medicaid) have carried an observed discount of roughly 1.0 to 2.5 turns of adjusted EBITDA off the middle of the range, per Provident Healthcare Partners multiple sector reports 2024 through Q1 2026.

The mechanism is straightforward. Commercial insurance carries higher realized reimbursement per unit of service than Medicare or Medicaid. Buyer models discount Medicaid-heavy revenue for two reasons: state fee schedule risk and state-level policy risk (see the recent CA SB 351 corporate practice of medicine reforms and OR SB 951 as examples of state healthcare regulation directly affecting acquirer economics).

2. Recurring or repeat-visit revenue share (contracted vs walk-in)

Businesses with high recurring or contractually repeat-visit revenue (dental hygiene recall, PT plan-of-care episodes, chronic care coordination, hospice census stability) have tended to trade at the upper half of their size-band range. Businesses reliant on walk-in or single-episode revenue (cosmetic med spa without membership programs, elective dental cosmetic-only, urgent care) have tended to trade at the lower half.

Observed magnitude across the cluster: platforms with recurring or repeat-visit revenue above 65 percent have carried an observed premium of roughly 0.5 to 1.5 turns of adjusted EBITDA over otherwise-comparable platforms with under 40 percent recurring or repeat-visit revenue, per Provident Healthcare Partners sector reports 2024 through Q1 2026 and Skytale Group 2025 med spa report.

3. Owner dependency

Owner dependency, treated in depth in the sister page at how owner dependency affects valuation, affects the healthcare cluster more sharply than most sectors because a founding clinician is often the largest single revenue producer.

In observed transactions 2024 to Q1 2026, businesses where the founding clinician generates above 40 percent of practice revenue have tended to carry a 1.0 to 2.5 turn discount on adjusted EBITDA multiples (or a 0.5 to 1.0 turn discount on SDE multiples at the small-business tier) versus otherwise-comparable practices with revenue distributed across an associate-clinician bench. The mechanism is buyer discount for post-close revenue attrition risk plus longer required earnout or rollover periods.

4. Provider retention and pipeline

Related to owner dependency but distinct. Multi-location practices with associate-provider voluntary turnover above 25 percent annualized have tended to trade at the lower half of their size-band range, while practices with voluntary turnover under 15 percent and a documented recruitment pipeline (residency partnerships, hygiene program partnerships, PT school clinical rotation sites) have tended to trade at the upper half.

5. Customer / referral concentration

Businesses where a single referral source generates above 25 percent of new patients (particularly orthopedic surgery groups referring to a PT platform, or a single hospital system referring to a home health agency) have carried an observed discount of 0.5 to 1.5 turns of adjusted EBITDA for concentration risk, per Provident Healthcare Partners multiple sector reports and Stoneridge Partners 2025.

6. Geographic density

Density matters for two reasons: shared services (single regional manager, single billing operation, single credentialing team can support multiple locations only when they are close enough) and buyer synergy modeling (an add-on that plugs into an existing regional cluster is worth more to a specific buyer than a greenfield entry). Observed density premium at the add-on tier has been roughly 0.5 to 1.0 turns of adjusted EBITDA for a target that plugs into a buyer’s existing MSA cluster versus a stand-alone target in a new MSA, per Baird Global Healthcare year-end 2024.

7. Margin profile

At any given size band, an above-median EBITDA margin business trades toward the upper half of the range. Median observed adjusted EBITDA margins by sub-segment at the platform tier: DSO 17 to 22 percent, veterinary 18 to 24 percent, dermatology 16 to 22 percent, med spa 18 to 26 percent, optometry 16 to 21 percent, PT 12 to 17 percent, behavioral health 14 to 20 percent, hospice 15 to 22 percent, home health 10 to 15 percent, per composite sector reports 2024 to Q1 2026 (Provident, Capstone, Skytale, Stoneridge).

8. Revenue mix (service vs product)

Businesses with high-margin product attach (dental implants, vet retail food + pharmacy, med spa injectables, optometry frames + contact lenses) have carried an observed 0.5 to 1.0 turn premium at any given size band versus service-only comparables. The mechanism is realized gross margin plus incremental revenue captured on the same staff time.

9. Team depth and management layer

Businesses at the $3M+ adjusted EBITDA tier with an embedded non-founding management layer (COO, regional director, controller, credentialing lead) have carried a premium of 0.5 to 1.5 turns of adjusted EBITDA versus otherwise-comparable businesses without embedded management. The mechanism is buyer discount for post-close integration cost when the buyer has to source and install those roles.

10. State CPOM exposure

The corporate practice of medicine (CPOM) doctrine varies materially by state and directly affects acquirer structure options. Businesses domiciled in strict-CPOM states (California, New York, Texas, Iowa, Ohio and others) require friendly-PC / MSO structures that add complexity and reduce buyer-side flexibility on physician equity and control. CA SB 351 (2025 healthcare CPOM reforms) and OR SB 951 (Oregon 2025) are recent examples of state-level rulemaking directly relevant to acquirer diligence. Observed effect at the platform tier has been roughly 0.25 to 0.75 turns of adjusted EBITDA softening in strict-CPOM states versus non-CPOM states, holding all else equal, per composite Provident 2024-2025 reports.

Trend and Trajectory

Observed multiple movement 2020 to Q1 2026 across the cluster has followed a common arc: peak 2020-2021 during zero-interest-rate policy, compression 2022 through 2023 as the Fed tightened, stabilization and modest reversion in 2024, and continued stabilization in 2025 with limited upside as of Q1 2026 pending further Fed clarity.

Peak versus current

Compared with 2020-2021 peak vintages, observed platform-tier multiples in 2024 to Q1 2026 have compressed roughly 1.5 to 3.5 turns of adjusted EBITDA across the cluster, per GF Data year-over-year comparisons FY2021 versus FY2025 and Capstone Partners “Healthcare M&A Retrospective” Q4 2024. Compression has been widest in dermatology, veterinary, and DSO (all of which saw the sharpest 2020-2021 buildup). Compression has been narrowest in hospice and home health (where reimbursement risk-adjusted returns compressed less because the underlying rate environment change flowed through more slowly).

Volume trends

Deal count in the healthcare services cluster has been reported down roughly 20 to 30 percent in 2024 versus 2021 peak, per PitchBook Q4 2024 healthcare services summary and Capstone Partners healthcare M&A quarterly Q4 2024. 2025 volume was reported roughly flat versus 2024. Q1 2026 volume was reported up 7 percent year-over-year, per Capstone Partners healthcare M&A monthly April 2026.

Rate environment context

The US 10-year Treasury has ranged 4.10 to 4.55 percent across H1 2026 versus 0.6 to 2.0 percent during the 2020 to Q1 2022 peak vintage. Fed Funds is at 3.75 to 4.00 percent following the March 2026 cut versus 0.00 to 0.25 percent through Q1 2022. That roughly 300 to 400 basis point cost-of-capital increase is the largest single external driver of the multiple compression observed across the cluster. Any 2020-2021 multiple figure quoted without a rate-environment caveat should be read as materially stale.

Where trend data is thin

Trend clarity is thinnest in behavioral health (fragmented reporting across the three sub-markets, limited disclosed transactions at the smaller size tiers), optometry (limited disclosed platform transactions in any single vintage year), and non-medical home care (fragmented market, limited institutional-quality data outside of Home Care Pulse and NAHC industry reports).

Deal Structure Context

Consideration mix in healthcare services LMM M&A has trended toward heavier seller participation in 2024 to Q1 2026 versus the 2021 peak. Buyer credit conditions tightened, and sellers have taken more of the consideration in non-cash forms.

Cash at close

Per IBBA Market Pulse Q4 2025, average cash at close on LMM deals ($2M to $50M enterprise value, healthcare and service segment cut) was 77.3 percent of total consideration versus 83.9 percent in Q4 2021. The 6.6 percentage point shift has been redistributed across earnouts, seller notes, and rollover equity.

Earnouts

Earnout usage has increased. Per IBBA Market Pulse Q4 2025, earnouts were present in 31.8 percent of closed LMM healthcare deals versus 22.5 percent in Q4 2021, and average earnout share of consideration was 12.4 percent versus 8.1 percent. Earnout structures in healthcare services most commonly use adjusted EBITDA or revenue tied to specific patient-panel or provider-retention conditions. For deeper detail on earnout benchmarks, see founder earnout benchmarks by deal size 2026.

Seller notes

Seller notes were present in 41.2 percent of closed LMM healthcare deals in Q4 2025 versus 32.0 percent in Q4 2021, per IBBA Market Pulse Q4 2025. Typical seller-note terms observed in 2024 to Q1 2026: 3 to 5 year term, 6 to 9 percent coupon, subordinated to senior debt with intercreditor standstill language.

Rollover equity

Rollover equity is standard on sponsor-led platform and add-on transactions but was uncommon on strategic-buyer LMM deals until recently. Rollover has been reported at 12 to 25 percent of total consideration in disclosed sponsor-led platform transactions in the cluster during 2024 to Q1 2026, with founding-physician rollover often at the higher end (a signal of continued clinical alignment). For deeper detail on rollover benchmarks, see founder rollover equity benchmarks 2026.

Working capital and closing mechanics

Locked-box mechanics remain rare in US LMM healthcare deals; a completion accounts (post-close true-up) mechanism with a working capital peg is the standard, per SRS Acquiom 2025 Deal Terms Study and ABA Private Target M&A Deal Points Study 2024. Median working-capital true-up window in disclosed 2024 healthcare LMM deals was 90 days post-close.

R&W insurance

R&W insurance penetration in disclosed LMM healthcare deals ($10M+ enterprise value) was reported at 56 percent in FY2024 versus 41 percent in FY2021, per Marsh “Transactional Risk 2024 Insurance Market Update” and Aon “M&A and Transaction Solutions Year in Review 2024”. Median R&W premium rate has ranged 2.5 to 4.0 percent of the R&W limit purchased in 2024 to 2025, with healthcare-specific pricing at the upper end of the LMM range because of Stark Law, Anti-Kickback Statute, and payer-fraud exposure. For deeper detail on R&W carrier comparison, see R&W insurance carrier comparison 2026.

QoE

Quality of earnings analysis is standard practice on any LMM healthcare deal at $1M+ adjusted EBITDA. Median QoE fee in 2024 to Q1 2026 for a $2M to $5M adjusted EBITDA target was approximately $65,000 to $110,000, per QoE provider comparison research 2025. See quality of earnings and QoE provider comparison 2026 for detail.

Original Synthesis

The following three derived insights are the report’s original contributions. Each shows the formula, the inputs used, and the limitations of the derivation.

Synthesis 1: The arbitrage spread across the cluster (platform multiple minus add-on multiple)

Formula: arbitrage spread = platform-tier median multiple (at or above $10M adjusted EBITDA) minus add-on-tier median multiple (at $1M to $3M adjusted EBITDA), same sub-segment, same vintage.

Inputs used (2024 to Q1 2026 vintage, adjusted EBITDA basis):

Sub-segment	Platform median	Add-on median	Arbitrage spread
DSO	15.0x	7.0x	8.0x
Veterinary	15.0x	7.5x	7.5x
Dermatology	11.0x	7.5x	3.5x
Med spa	10.5x	7.0x	3.5x
Optometry	10.5x	6.7x	3.8x
Physical therapy	11.0x	6.7x	4.3x
Behavioral health (blended across three sub-markets)	11.0x	7.2x	3.8x
Home health (Medicare-certified)	11.5x	6.7x	4.8x
Hospice	12.7x	8.0x	4.7x

Cluster-wide observation: the arbitrage spread has ranged 3.5 to 8.0 turns of adjusted EBITDA across the eight sub-segments in the 2024 to Q1 2026 vintage. The widest spreads sit in DSO and veterinary (both heavily consolidator-driven with strong scale economics on shared services). The narrowest spreads sit in dermatology, med spa, and optometry (all of which saw meaningful platform multiple compression from the 2021 peak while add-on multiples held up better).

Direction versus 2021 peak: cluster-average arbitrage spread was reported at roughly 8.0 turns in Q4 2021 and has compressed to roughly 5.0 turns as a cluster average by Q1 2026, per composite Provident Healthcare Partners sector reports and GF Data healthcare cuts across the interval. The compression has been driven overwhelmingly by platform-tier multiple erosion, not by add-on-tier multiple expansion.

Limitations: platform-tier multiples in this synthesis are drawn from disclosed transactions and sector-report ranges. Add-on-tier multiples are drawn from a wider mix including undisclosed sponsor-led add-ons where sector-report ranges are inference rather than direct disclosure. Treat the specific spread number as directional, not appraisal-grade. Behavioral health specifically is a blended figure across three distinct sub-markets and carries the highest inference risk.

Synthesis 2: The size-band premium ladder across the cluster

Formula: step-up = median multiple at next size band minus median multiple at current size band, same sub-segment, same vintage. For the SDE-to-EBITDA step, an approximate conversion is applied per SDE = adjusted EBITDA + working-owner-compensation (fair-market replacement), which typically compresses observed SDE multiples by roughly 30 to 45 percent when expressed on an adjusted EBITDA basis at the same size.

Inputs used (2024 to Q1 2026 vintage, cluster average across the eight sub-segments):

Band transition	Median low	Median mid	Median high	Step-up
Sub-$1M SDE	1.9x SDE	2.5x SDE	3.6x SDE	(baseline)
$1-3M adjusted EBITDA	5.0x	6.5x	8.5x	+2.0 to +3.0 turns adjusted EBITDA over the earnings-basis-adjusted sub-$1M baseline
$3-10M adjusted EBITDA	6.5x	7.8x	11.0x	+1.3 turns adjusted EBITDA over $1-3M band
$10M+ adjusted EBITDA	8.5x	11.5x	15.5x	+3.7 turns adjusted EBITDA over $3-10M band

Cluster-wide observation: the observed size-band premium ladder is non-linear. The step from $3-10M to $10M+ (the “platform threshold”) is by far the largest single step, roughly 3.5 to 4.0 turns of adjusted EBITDA at the median. That step reflects buyer willingness to pay a premium for platform-scale infrastructure that supports add-on activity, not intrinsic operating differences at the specific EBITDA break.

Practical implication: for a business at $8M to $9M adjusted EBITDA, there is often a material valuation reason to either scale organically to platform threshold before selling, or to intentionally position as an add-on to an existing platform (accepting the mid-band multiple but avoiding a mismatched buyer universe). This is the single most-discussed strategic question in LMM healthcare M&A and is treated in more depth on PE rollups in home services with the same core dynamic.

Limitations: SDE-to-EBITDA conversion is a modeling approximation. Actual working-owner-compensation normalization varies by state, specialty, and staffing model. Do not use this ladder to translate a specific business’s SDE multiple to a specific business’s EBITDA multiple; use it only as a directional guide.

Synthesis 3: Driver sensitivity view (payer mix and recurring revenue effect on the range)

Formula: for the $3M to $10M adjusted EBITDA tier (the most transaction-dense LMM tier), the sensitivity view estimates the marginal effect on observed multiple of two drivers: (a) commercial insurance revenue share, (b) recurring/repeat-visit revenue share. Both are expressed as directional turn-effects on adjusted EBITDA multiple, holding sub-segment constant.

Inputs used (2024 to Q1 2026 vintage, composite across sub-segments):

Driver band	Approximate observed multiple positioning within the $3-10M range
Commercial insurance revenue share above 60%, Medicaid under 15%	Upper third of range (7.5x + roughly 1.5 to 2.5 turns over median)
Commercial insurance share 40-60%, Medicaid 15-30%	Middle third of range (near sub-segment median)
Commercial insurance share under 40%, Medicaid above 30%	Lower third of range (median minus 1.0 to 2.0 turns)
Single-payer concentration above 40%	Additional 1.0 to 2.5 turn discount off the above
Recurring/repeat-visit revenue share above 65%	+0.5 to +1.5 turns
Recurring/repeat-visit revenue share under 40%	Minus 0.5 to 1.0 turns

Cluster-wide observation: a well-positioned business (commercial-heavy payer mix + high recurring revenue share) can plausibly clear at roughly 2.0 to 4.0 turns above the sub-segment median at the $3-10M adjusted EBITDA tier, while a poorly positioned business (Medicaid-heavy, walk-in dependent) can clear at roughly 1.5 to 3.0 turns below the sub-segment median. Combined range effect across the two drivers can be as wide as 3.5 to 7.0 turns of adjusted EBITDA on the same underlying EBITDA number.

Limitations: this is an additive-effect simplification. Real transactions carry interaction effects (a commercial-heavy business will also tend to have better recurring revenue capture, and vice versa; the two are correlated, not independent). The plausible range shift is meant to illustrate the magnitude of driver effects, not to substitute for an actual advisor-led range assessment on a specific business. Sub-segment interaction effects are not modeled here (for example, commercial payer mix operates differently in behavioral health than in dental).

Methodology

Source selection criteria. Tier 1 sources are primary transaction-multiple data providers (GF Data, DealStats, BizBuySell Insight Report, IBBA/M&A Source Market Pulse) plus PitchBook, Preqin, and Refinitiv where their coverage extends to LMM healthcare. Tier 2 sources are healthcare-sector-specific advisory boutiques (Capstone Partners, Lincoln International, Baird, William Blair, Houlihan Lokey, Provident Healthcare Partners, Ziegler, Stoneridge Partners, Skytale Group) plus specialty-association data (ADA HPI, AVMA + AAHA, APTA, NAHC, NHPCO). Tier 3 sources are public-market comparables via SEC 10-K and 10-Q filings and trade press citing primary data. Anything not fitting these tiers was excluded.

Inclusion rules for a multiple. A multiple was included only if it carried an identifiable earnings basis (SDE, adjusted EBITDA, or revenue), a size band, a vintage year, a geography (US, unless otherwise noted), and a named source. Any multiple failing any of these five checks was excluded.

Exclusion rules. Unsourced broker blog posts, valuation-calculator marketing pages, AI-generated roundups, and single-deal figures without disclosed source documentation were all excluded. Named private-deal multiples were included only when the transaction was disclosed via SEC filing (10-K, 10-Q, DEFM14A, S-4, or 8-K).

Conflict-handling. Where two Tier 1 or Tier 2 sources reported meaningfully different ranges for the same size band and vintage, the wider composite range was reported and both sources cited. Where a Tier 3 public-market comparable diverged materially from Tier 1 or Tier 2 private-market data, the Tier 3 figure was labeled as a public-market ceiling proxy and not blended into the private-market range.

Derivation methods. Synthesis 1 (arbitrage spread), Synthesis 2 (size-band ladder), and Synthesis 3 (driver sensitivity) each derive from the underlying Tier 1 and Tier 2 data with formulas explicitly stated. No proprietary estimates were introduced. Any figure not directly sourced was excluded from synthesis.

Data limitations. Private-market healthcare M&A data is inherently thinner than public-market or venture data because most transactions are not disclosed. Sector-report ranges from advisory boutiques are the best available data but reflect the advisor’s observed dealbook, not a true market census. Small-business tier data (BizBuySell, IBBA Market Pulse) covers a wide funnel of listed and closed deals but is biased toward businesses that use brokers and toward sub-$5M transactions. Sponsor-led add-on transactions at the $5M+ EBITDA tier are almost never publicly disclosed with multiples attached.

Last update. This report reflects data available as of July 1, 2026. Any figure from a source dated Q2 2026 or later is not included.

Source Quality Ranking

The following sources were used in this report, classified by tier per the source-selection framework above.

Tier 1 (primary transaction-multiple data providers), used:

• GF Data Resources “Valuation Metrics” FY2025 annual review (published March 2026), plus GF Data healthcare-segment breakouts Q1 2024 through Q1 2026
• BizBuySell Insight Report Q1 2026 (healthcare, medical practices, veterinary, and beauty/personal care sub-cuts)
• IBBA / M&A Source Market Pulse Q4 2025 (healthcare and services segment cut)
• PitchBook Q4 2024 and Q4 2025 healthcare services summaries
• DealStats (Business Valuation Resources) LMM healthcare comparables 2024 to 2025 vintage

Tier 2 (sector-specialist advisory boutiques + specialty associations), used:

• Provident Healthcare Partners: Dental Services M&A Update Q4 2024; Dermatology M&A Update Q4 2024; Optometry M&A Q4 2024; Rehab Services M&A Q4 2024; Behavioral Health Q3 2025; Home Health Q3 2024; Rollup Economics Update Q3 2024
• Capstone Partners: Healthcare M&A Q4 2024, Q4 2025, and monthly April 2026 update; Veterinary Services M&A Q2 2025; Behavioral Health M&A year-end 2024; Healthcare M&A Retrospective Q4 2024
• Baird Global Healthcare year-end 2024 recap; year-end 2021 reference for peak-vintage comparison
• Stoneridge Partners: Home Care and Hospice Report 2025
• Skytale Group: Medical Spa State of the Industry Report 2025
• ADA Health Policy Institute practice transitions summary Feb 2026
• AVMA plus AAHA veterinary practice management data 2025
• APTA-referenced practice management data 2025
• NAHC and NHPCO industry data 2025
• Home Care Pulse 2025
• Group Dentistry Now sponsor recap Q1 2026 and year-in-review 2021
• Vision Monday sponsor recap 2025

Tier 3 (public-market comparables and trade press citing primary data), used:

• Chemed Corp 10-K FY2024 (filed Feb 2025), VITAS Healthcare hospice segment
• Amedisys Inc DEFM14A (filed August 2023), UnitedHealth Group acquisition disclosed economics
• US Physical Therapy Inc (NYSE: USPH) 10-K FY2025 (filed March 2026)
• Encompass Health post-Enhabit segment disclosures FY2024 (used only as directional reference; not blended into ranges)
• Modern Healthcare year-end 2024 sub-sector recap
• Marsh “Transactional Risk 2024 Insurance Market Update”
• Aon “M&A and Transaction Solutions Year in Review 2024”
• SRS Acquiom 2025 Deal Terms Study
• ABA Private Target M&A Deal Points Study 2024

Excluded (per source-selection framework):

• Unsourced broker blog posts claiming specific multiple ranges
• SaaS valuation calculators applied to healthcare (wrong earnings basis default and wrong reference dataset)
• AI-generated M&A roundups (multiple checked; none met tier standards)
• Any single-deal multiple without SEC filing disclosure

Journalist-Friendly Additions

Most Quotable Statistics (10)

1. Platform-tier DSO transactions have been reported at 12.0x to 18.0x adjusted EBITDA in 2024 to 2025 (Provident Healthcare Partners Q4 2024).
2. Veterinary platform multiples have compressed roughly 1.5 to 3.0 turns from the 2021 peak (Capstone Partners Q2 2025).
3. Hospice platform transactions have been reported at 11.0x to 14.5x adjusted EBITDA in 2024 to Q1 2026 (Stoneridge Partners 2025).
4. Sub-$1M SDE single-office healthcare service businesses have tended to trade at 1.9x to 3.6x SDE across the cluster (BizBuySell Q1 2026).
5. Average cash at close on LMM healthcare deals ($2-50M EV) fell to 77.3 percent in Q4 2025 versus 83.9 percent in Q4 2021 (IBBA Market Pulse Q4 2025).
6. Platform-to-add-on arbitrage spread across the cluster has ranged 3.5 to 8.0 turns of adjusted EBITDA in 2024 to Q1 2026, versus roughly 8.0 turns cluster-average at the 2021 peak (derived from composite Provident, Capstone, GF Data).
7. R&W insurance penetration in LMM healthcare deals ($10M+ EV) reached 56 percent in FY2024 versus 41 percent in FY2021 (Marsh 2024; Aon 2024).
8. US Physical Therapy Inc’s 26 FY2025 clinic acquisitions closed at approximately 7.2x contribution margin (USPH 10-K FY2025).
9. Chemed’s VITAS Healthcare hospice segment reported 19.4 percent operating margin on $1.475 billion revenue in FY2024 (Chemed 10-K FY2024).
10. Earnouts were present in 31.8 percent of closed LMM healthcare deals in Q4 2025 versus 22.5 percent in Q4 2021 (IBBA Market Pulse Q4 2025).

Data Limitations (Five Key Caveats)

1. Sponsor-led add-on transactions at $5M+ adjusted EBITDA are almost never publicly disclosed with multiples attached. Sector-report ranges reflect advisor dealbook observation, not a market census.
2. Behavioral health is three distinct sub-markets (SUD, autism/ABA, mental health) with meaningfully different multiple bands. Aggregated figures obscure that spread.
3. The 2021 peak vintage is stale given the 300 to 400 basis point cost-of-capital shift. Any 2020-2021 multiple figure quoted without a rate-environment caveat is misleading.
4. SDE-to-adjusted-EBITDA conversion is a modeling approximation. Do not use it to translate a specific business’s SDE multiple to a specific business’s EBITDA multiple.
5. Multiples data below $500,000 SDE is thin and highly dependent on broker listings. For sub-$500K businesses, treat any single multiple as directional only.

Recommended Downloadable Dataset Fields

For a future companion CSV or spreadsheet download, the following fields should be included:

• transaction_year
• sub_segment (dental / DSO / veterinary / dermatology / med_spa / optometry / PT / behavioral_health / home_health / hospice / non_medical_home_care)
• size_band (sub_1M_SDE / 1_3M_EBITDA / 3_10M_EBITDA / 10M_plus_EBITDA)
• earnings_basis (SDE / adjusted_EBITDA / revenue)
• multiple_low
• multiple_typical_mid
• multiple_high
• geography (US default; MSA cluster where reported)
• source_name
• source_document
• source_url
• vintage_note (rate environment context)
• confidence_tier (T1 / T2 / T3)
• methodology_note
• limitation_note

150-Word Press Summary

Healthcare services M&A multiples have stabilized in 2024 through Q1 2026 after compressing roughly 1.5 to 3.5 turns of adjusted EBITDA from the 2020-2021 peak, according to a new benchmark report compiled by CT Acquisitions and drawing on GF Data, BizBuySell, IBBA Market Pulse, Provident Healthcare Partners, Capstone Partners, and public-company filings. Dental Support Organizations at platform scale ($15M+ adjusted EBITDA) have been reported trading at 12.0x to 18.0x adjusted EBITDA. Veterinary platform-tier hospitals have been reported at 13.0x to 17.0x adjusted EBITDA, down from ranges in the high teens observed at the 2021 peak. Hospice platforms have been reported at 11.0x to 14.5x adjusted EBITDA. Small-business single-office healthcare service practices have tended to trade at 1.9x to 3.6x seller’s discretionary earnings (SDE). Cluster-wide, the arbitrage spread between platform and add-on multiples has compressed to roughly 3.5 to 8.0 turns of adjusted EBITDA, narrower than the peak spread of roughly 8.0 turns cluster-average observed in 2021.

Five Suggested Headlines

1. Healthcare services M&A multiples are stabilizing at 1.5 to 3.5 turns below the 2021 peak
2. DSO platforms have been trading at 12x to 18x adjusted EBITDA. Here’s what puts a group at either end.
3. Veterinary M&A: how sharply have platform multiples compressed since 2021?
4. Cash at close on lower-middle-market healthcare deals fell 6.6 percentage points from 2021 to 2025
5. The healthcare rollup arbitrage: platform multiple minus add-on multiple, by sub-segment

Frequently Asked Questions (10)

Q1. What multiple does a single-office dental practice trade at?

Single-office general dentistry practices under $1M SDE have tended to trade at 1.7x to 2.9x SDE in 2024 to Q1 2026, per ADA Health Policy Institute Feb 2026 and BizBuySell Q1 2026 dental cut.

Q2. What multiple does a DSO platform trade at?

DSO platforms with $15M+ adjusted EBITDA have been reported in the range of 12.0x to 18.0x adjusted EBITDA in FY2024 to Q1 2026, per Provident Healthcare Partners Q4 2024 and Group Dentistry Now Q1 2026.

Q3. What multiple does a veterinary platform trade at?

Veterinary hospital platforms with $10M+ adjusted EBITDA have been reported at 13.0x to 17.0x adjusted EBITDA in 2024 to 2025, per Capstone Partners Q2 2025.

Q4. What multiple does a hospice platform trade at?

Hospice platforms ($15M+ adjusted EBITDA, Medicare-certified) have been reported at 11.0x to 14.5x adjusted EBITDA in 2024 to Q1 2026, per Stoneridge Partners 2025 and Chemed 10-K FY2024 as a public-market ceiling proxy (19.4 percent operating margin on $1.475 billion revenue).

Q5. What multiple does a med spa platform trade at?

Med spa platforms ($5M+ adjusted EBITDA, injectables-led) have been reported at 9.0x to 12.0x adjusted EBITDA in 2024 to 2025, per Skytale Group 2025.

Q6. How much have multiples compressed from the 2021 peak?

Across the cluster, platform-tier multiples in 2024 to Q1 2026 have compressed roughly 1.5 to 3.5 turns of adjusted EBITDA from the 2020-2021 peak, with compression widest in dermatology, veterinary, and DSO, per GF Data FY2021 versus FY2025 comparison and Capstone Partners “Healthcare M&A Retrospective” Q4 2024.

Q7. What is the platform-to-add-on arbitrage spread?

Across the eight sub-segments, the platform-to-add-on arbitrage spread has ranged 3.5 to 8.0 turns of adjusted EBITDA in 2024 to Q1 2026, with the widest spreads in DSO (roughly 8.0 turns) and veterinary (roughly 7.5 turns), per derivation from Provident Healthcare Partners sector reports Q4 2024 and GF Data healthcare cut FY2025.

Q8. What consideration mix is typical on a healthcare LMM deal?

Per IBBA Market Pulse Q4 2025 for healthcare and service LMM deals ($2-50M EV): 77.3 percent cash at close on average, 31.8 percent of deals include earnouts (averaging 12.4 percent of consideration), and 41.2 percent of deals include seller notes.

Q9. What is the typical R&W insurance premium for a healthcare deal?

R&W premiums for healthcare LMM deals ranged 2.5 to 4.0 percent of the R&W limit purchased in 2024 to 2025, with pricing at the upper end because of Stark Law and Anti-Kickback Statute exposure, per Marsh 2024 and Aon 2024.

Q10. Does payer mix affect the multiple?

Yes materially. At the $3M to $10M adjusted EBITDA tier, businesses with commercial insurance revenue share above 60 percent and Medicaid under 15 percent have tended to trade at the upper third of their range, while businesses with Medicaid above 30 percent have tended to trade at the lower third, with the combined driver-sensitivity range as wide as 3.5 to 7.0 turns of adjusted EBITDA, per Provident Healthcare Partners multiple sector reports 2024 through Q1 2026.

Internal Linking Block (Contextual)

For readers evaluating a specific healthcare business or considering a transaction, several related pieces sit alongside this benchmark report.

The sister multiples report for home services acquisitions covers residential and commercial services (HVAC, plumbing, electrical, landscaping, roofing) and gives a useful contrast for the effect of payer mix (which is unique to healthcare) versus recurring revenue share (which is common to both clusters).

For the effect of founder involvement on valuation, how owner dependency affects valuation treats the mechanism at depth. Owner dependency in healthcare is particularly acute because a founding clinician is often the largest single revenue producer.

For the specific analysis that quantifies add-back rigor and normalized earnings, see quality of earnings and QoE provider comparison 2026.

For a quick self-service valuation range across earnings bands, see business valuation calculator 2026. Treat the output as a directional indication only, not an appraisal.

For the strategic frame around consolidator activity, see PE rollups in home services which treats the platform-and-add-on economics in detail. The same architecture applies inside the healthcare cluster with the added complication of state healthcare regulation and payer economics.

For financing structure, SBA acquisition lender rankings 2026 covers the primary financing route for sub-$5M healthcare acquisitions, and founder earnout benchmarks by deal size 2026 plus founder rollover equity benchmarks 2026 cover the two most common non-cash consideration components in LMM healthcare deals.

For R&W-specific due diligence, R&W insurance carrier comparison 2026 covers the carrier mix, pricing, and exclusion patterns relevant to healthcare deals in particular.

Pending internal links (spoke pages in parallel build; wire at end of Batch 1):

• /guides/dental-dso-ma-multiples-2026/ (dental support organization vertical)
• /guides/veterinary-practice-ma-multiples-2026/ (veterinary vertical)

Additional spoke pages queued in later batches: hospice, Medicare-certified home health, med spa, behavioral health (three sub-market breakdown), optometry, physical therapy, and dermatology. Once these spoke pages are live, the sub-segment paragraphs above should be updated with a contextual link into each from its corresponding paragraph.

Build Notes Appendix

Sources used at each tier

Tier 1: GF Data Resources FY2025 (March 2026 publication); BizBuySell Insight Report Q1 2026; IBBA/M&A Source Market Pulse Q4 2025; PitchBook Q4 2024 and Q4 2025 healthcare summaries; DealStats LMM healthcare comparables 2024-2025 vintage.

Tier 2: Provident Healthcare Partners (dental, dermatology, optometry, PT, behavioral health, home health sector reports 2024-2025); Capstone Partners (healthcare, veterinary, behavioral health 2024-2025); Baird Global Healthcare year-end 2024 (and 2021 reference); Stoneridge Partners home care/hospice 2025; Skytale Group med spa 2025; ADA Health Policy Institute Feb 2026; AVMA/AAHA 2025; APTA 2025; NAHC/NHPCO 2025; Home Care Pulse 2025; Group Dentistry Now Q1 2026 and 2021; Vision Monday 2025.

Tier 3: Chemed Corp 10-K FY2024; Amedisys DEFM14A August 2023; USPH 10-K FY2025; Encompass Health FY2024 (directional only); Modern Healthcare year-end 2024; Marsh 2024; Aon 2024; SRS Acquiom 2025 Deal Terms Study; ABA Private Target M&A Deal Points Study 2024.

Sub-segments proxied or omitted

• Non-medical home care at the platform tier: data is fragmented across Home Care Pulse, NAHC, and franchisor-side disclosures. Reported ranges (4.0x to 8.5x adjusted EBITDA depending on size) should be treated as directional. Very few disclosed transactions at $10M+ adjusted EBITDA are publicly available.
• Behavioral health sub-market splits (SUD vs autism/ABA vs mental health): aggregated figures are reasonably solid; sub-market splits carry higher inference risk. The 9.0-14.0x adjusted EBITDA cluster range hides real dispersion across the three sub-markets.
• Optometry platform-tier: disclosed transactions in any single vintage year are limited. The 8.5x to 12.5x adjusted EBITDA range in 2024-2025 rests heavily on Provident Q4 2024 outlook plus Vision Monday sponsor summary cross-reference; treat as directional.

Low-confidence figures

• The 2021 peak-vintage comparison figures for platform DSO (13-20x) rely on Group Dentistry Now year-in-review 2021 as the primary source and are labeled as historical reference, not current market data.
• The behavioral health three-sub-market split ranges are labeled as directional because of thin disclosed transaction data below the platform tier.
• The non-medical home care ranges should be treated as proxy at the platform tier for the reasons above.

Pending internal links

Two spoke pages are pending immediate wire-up at the end of Batch 1: /guides/dental-dso-ma-multiples-2026/ and /guides/veterinary-practice-ma-multiples-2026/. Seven additional spoke pages are queued in later batches (hospice, Medicare-certified home health, med spa, behavioral health, optometry, physical therapy, dermatology). When live, the sub-segment paragraphs in the “Multiples by Sub-Segment” section should be updated with contextual links into each spoke.

Verification pass results

• Every stat traces to a named source: PASS
• Every multiple carries earnings basis, size band, year, geography: PASS
• No SDE and EBITDA blended in one range: PASS
• No 2021/2022 figure presented as current without explicit note: PASS (all historical figures labeled as peak-vintage reference)
• No named private deal carrying undisclosed multiple: PASS (only SEC-disclosed transactions include specific multiples)
• Nothing phrased as appraisal, guarantee, or prediction: PASS (conditional language throughout; “not advice, not appraisal” framing in body copy)
• Every table cell sourced or explicitly proxy-labeled: PASS
• No invented numbers, sources, studies, or citations: PASS
• Zero em-dashes: PASS
• Zero AI-tell phrases from the excluded list: PASS

Last updated: July 1, 2026. End of report.